Biospecimen Acquistion and Molecular Annotation

基因组和蛋白质组技术的进展使生物样品和 相应的数据对于了解中风等人类疾病的分子基础至关重要。 因此，Biosecimen采购核心的目标是收集、加工、储存和分发 在这项建议的临床试验和常规试验中来自患者的生物检疫 在这个医学中心治疗病人。这个核心的第一个目标是支持收集和 处理登记的患者的血清、血浆、脑脊液和基因组DNA(每年约50例) 项目1-3中所述的研究。样本将在研究开始时和在多个时间点收集 在允许的情况下，创建一组可以随着时间的推移进行分析并与临床相关的生物谱系 进步。当可用和适当时，核心还将提供支持以收集组织标本 从病人那里。该核心第二个目标是创建一个更具扩展性的生物样品资源，包括 所有卒中患者(每年-800人)的单一时间点血清、血浆和基因组DNA 机构。该核心第三个目标是创建一份可用生物菌种资源的清单，并确定 可由授权的内部和外部SPOTRIAS调查人员访问的数据，用于 共享这一生物谱系资源促进卒中临床相关新研究的目的 预防和治疗。为了实现这些目标，该核心将利用广泛的基础设施 已经为我们机构的生物标本管理开发了这项技术。患者招募和 同意将与患者核心B协调。生物检疫和相关数据管理将 与生物统计核心D协调，并使用成熟的诚实经纪人机制取消身份识别。 标本处理、储存和质量保证将采用标准化的操作程序， 已经在我们的机构组织库中存在了七年。生成和生物信息学 基因组多态(SNP)数据的管理(尽管在当前的任何 项目)也将得到该机构的基因芯片设施的支持。最后，生物质学数据 管理和数据发布将利用我们机构的努力来发展企业类， 可通过网络访问的生物系数据库(CaTISSUE Core)。

Adavnces in genomic and proteomic technologies have made the availability of biospecimens and corresponding data critical to understanding the molecular basis of human diseases such as stroke. Accordingly, the goal of the Biospecimen Procurement Core is to collect, process, store, and distribute biospecimens from patients in the context of both this proposal's clinical trials and during the routine treatment of patients at this medicial center. The first aim of this core is to support the collection and processing of serum, plasma, CSF, and genomic DMA from patients (approximately 50 per year) enrolled in studies described in projects 1-3. Samples will be collected upon study entry and over multiple time points as permissable, to create a set of biospecimens that can be analyzed over time and correlated with clinical progression. When avaialble and appropriate, the core will also provide support to collect tissue specimens from patients. The second aim of this core is to create a more expansive biospecimen resource consisting of single time-point serum, plasma, and genomic DMA from all stroke patients (-800 per year) seen at this institution. The third aim of this core is to create an inventory of available biospecimen resources and deidentified data that can be accessed by authorized intramural and extramural SPOTRIAS investigators, for the purposes of sharing this biospecimen resource to promote novel clinical correlative studies in stroke prevention and treatment. To accomplish these goals, this core will capitalize on the extensive infrastructure that has already been developed for biospecimen management at our institution. Patient recruitment and consenting will be coordinated with Patient Core B. Biospecimens and associated data mangement will be coordinated with Biostatistics Core D and de-identified using a well-established honest broker mechanism. Specimen processing, storage, and quality assurance will utilize standardized operating procedures that have been in place in our institutional tissue bank for the past seven years. Generation and bioinformatic management of genomic polymorphism (SNP) data (although not specifically proposed in any of the current projects) will also be supported by the institution's GeneChip facility. Finally, biospecimen data management and data publishing will take advantage of efforts at our institution to develop an enterpriseclass, web-accessible biospecimen database (caTISSUE Core).